Biotech Venture Firm Closes $250 Million Opportunity Fund

January 2, 2019

Atlas Venture, a leading venture capital firm investing in breakthrough biotech innovation, today announced the closing of its first Opportunity Fund, raising $250 million in an oversubscribed fundraise. With Atlas Venture Opportunity Fund I (AVOF I), the firm will invest in existing Atlas portfolio companies as they progress.

Together with experienced entrepreneurs-in-residence, Atlas Venture creates new biotech startups to discover and develop novel medicines. The firm takes a hands-on approach to building companies and incubates many of them in the firm’s Kendall Square space. Atlas’ early stage funds, which focus on new company formation, are complemented by AVOF I which will invest in high-potential portfolio companies as they grow through Series B financings and beyond.

Atlas Venture has been building biotechnology companies for more than two decades. The same team of five investing partners will invest AVOF I: Kevin Bitterman, Bruce Booth, Jean-François Formela, David Grayzel, and Jason Rhodes.

CP Wire

Submit an article to cafepharma's CP Wire. Click here to find out more.

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.